Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Step-down of enalapril treatment for arterial hypertension
Autore:
Gonzalez-Juanatey, JR; Reino, AP; Garcia-Acuna, JM; Gonzalez-Juanatey, C; Valdes, L; Cabezas-Cerrato, J;
Indirizzi:
Univ Santiago de Compostela, Complexo Hosp, Dept Cardiol, Santiago De Compostela, Spain Univ Santiago de Compostela Santiago De Compostela Spain postela, Spain
Titolo Testata:
HYPERTENSION
fascicolo: 6, volume: 34, anno: 1999,
pagine: 1287 - 1292
SICI:
0194-911X(199912)34:6<1287:SOETFA>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONVERTING-ENZYME-INHIBITOR; LEFT-VENTRICULAR MASS; SYSTEMIC HYPERTENSION; RESISTANCE ARTERIES; BLOOD-PRESSURE; THERAPY; HYPERTROPHY; REDUCTION; DISEASE;
Keywords:
hypertension, essential; hypertension, arterial; enalapril;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Gonzalez-Juanatey, JR Hosp Xeral de Galicia, Dept Cardiol, Galeras S-N, Santiago De Compostela 15705, Spain Hosp Xeral de Galicia Galeras S-N Santiago De Compostela Spain 15705
Citazione:
J.R. Gonzalez-Juanatey et al., "Step-down of enalapril treatment for arterial hypertension", HYPERTENSIO, 34(6), 1999, pp. 1287-1292

Abstract

Enalapril treatment (20 mg every 12 hours) of 24 patients with essential hypertension and left ventricular (LV) hypertrophy established normal blood pressures after 8 weeks, and after 5 years, it had reduced LV mass index by39% (from 148+/-34 to 90+/-16 g/m(2)) and had normalized LV structure and function and QT dispersion. Stepwise reduction of the enalapril dosage from40 to 30, 20, 10, and 5 mg/d during the eighth year caused no significant change in blood pressure, LV structure, LV systolic function, or QT dispersion, which all likewise remained unaltered during an additional 2-year period of the 5-mg/d regimen. We conclude that for hypertensive patients in whom prolonged treatment with high doses of enalapril has normalized blood pressure, LV structure, LV function, and QT dispersion, the dose may be reduced as much as 8-fold without detriment to cardiovascular control. The use ofsmaller doses is evidently advantageous from the point of view of health costs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/11/20 alle ore 22:36:05